% | $
Quotes you view appear here for quick access.

Ironwood Pharmaceuticals, Inc. Message Board

galaberge 10 posts  |  Last Activity: Apr 20, 2016 7:31 PM Member since: Mar 5, 2002
  • Michael S. Okun, MD, also author of the Parkinson bestseller, Parkinson's Treatment: 10 Secrets to a Happier Life, is considered a world's authority on Parkinson's disease treatment, and his publications provide a voice and an outlet to empower people living all over the world. He is currently Administrative Director and Co-director of the University of Florida Center for Movement Disorders and Neurorestoration. The center he runs is unique in that it is comprised of over 45 interdisciplinary faculty members from diverse areas, all of whom are dedicated to care, outreach, education and research. Dr. Okun has been dedicated to this interdisciplinary care concept, and since his appointment as the National Medical Director for the National Parkinson Foundation in 2006, he has worked with the 43 international NPF centers of excellence to help foster the best possible environments for care, research and outreach in Parkinson disease, dystonia, Tourette, and movement disorders. Dr. Okun has been supported by grants from the National Parkinson Foundation, the National Institutes of Health, the Parkinson Alliance, and the Michael J. Fox Foundation for Parkinson’s Disease Research, and he currently runs the online international “Ask The Expert” forums, on the National Parkinson Foundation website. The forum is a free service that answers questions from every continent (except Antartica) and has over 10,000 postings in the last 3 years alone. Dr. Okun has dedicated much of his career to the development of care centers for people suffering with movement disorders, but has also has enjoyed a prolific research career exploring non-motor basal ganglia brain features, and he has participated in pioneering studies exploring the cognitive, behavioral, and mood effects of deep brain stimulation (DBS).....continued

    Sentiment: Strong Buy

  • Reply to

    FDA Panel Backs Approval of Pimavanserin

    by galaberge Apr 20, 2016 4:06 PM
    galaberge galaberge Apr 20, 2016 4:30 PM Flag

    The author is....the Dr. Michael S. Okun himself, NPF's National Medical Director ! He wrote as if it was a done fact.

    Sentiment: Strong Buy

  • Here is an article found in the National Parkinson Foundation

    I quote :" What's Hot in PD?: As a New Drug Gains FDA Approval for Parkinson’s Disease Psychosis (Nuplazid), Should We Fear Using it? "

    Here is the link : " parkinsonDOTorg/find-help/blogs/whats-hot/april-2016 "

    Good reading


    Sentiment: Strong Buy

  • Here is a link stating the purchases of the BB: " edgarDOTsecDOTgov/Archives/edgar/data/1070494/000163859916000776/xslF345X03/doc4_3894DOTxml "


    Sentiment: Strong Buy

  • Reply to

    Baker Brothers are buying again

    by hawkihop1 Apr 2, 2016 5:44 PM
    galaberge galaberge Apr 3, 2016 7:50 PM Flag


  • ........(takes a little while to open post - a lot in here).

    Here is the link; " investorvillageDOTcom/smbd.asp?mb=523&mn=634&pt=msg&mid=13575176 "

    You will enjoy reading this excellent compilation. Enjoy and GLTA next coming days and weeks.

    Sentiment: Strong Buy

  • galaberge by galaberge Mar 26, 2016 4:24 PM Flag

    I quote "Fortune " and the link " fortuneDOTcom/2016/03/25/new-blockbuster-drugs-to-watch/ "

    7 New Blockbuster Drugs to Watch in 2016 by Laura Lorenzetti @lauralorenzetti March 25, 2016, 8:06 AM EDT

    "ACADIA Pharmaceuticals

    Drug: Nuplazid

    Indication: Parkinson’s disease psychosis

    2020 Forecast Sales: $1.41 billion

    ACADIA’s ACAD 0.30% nuplazid could be the first and only drug on the market to help treat Parkinson’s disease psychosis, which affects up to 40% of Parkinson’s patients. Clinical trials have shown that the drug does not worsen motor symptoms, a vital factor for these patients, while improving night-time sleep, daytime wakefulness, and caregiver burden. Nuplazid may also work in other psychosis settings, such as schizophrenia and Alzheimer’s disease psychosis. The combination of those three diseases means ACADIA’s drug has a potentially massive and therefore lucrative market."

    GLTA in the next days and weeks

    Sentiment: Strong Buy

  • Fourth-Quarter 2015 Net Sales of $244.5 Million, Up 135 Percent; Fourth-Quarter 2015 Adjusted EBITDA of $122.5 Million; GAAP Net Income of $24.0 Million; Fourth-Quarter 2015 Adjusted Operating Cash Flow of $154.0 Million; GAAP Operating Cash Flow of $134.9 Million; Full-Year 2015 Net Sales of $757.0 Million, Up 155 Percent; Full-Year 2015 Adjusted EBITDA of $362.1 Million; GAAP Net Income of $39.5 Million; Full-Year 2016 Net Sales Guidance of $1.025 to $1.050 Billion and Full-Year 2016 Adjusted EBITDA Guidance of $505 to $520 Million

    Sentiment: Strong Buy

  • galaberge galaberge Feb 19, 2016 3:28 PM Flag

    Mule-Excellent findings and explamations. Congrats


    Sentiment: Strong Buy

  • Aquinox is currently developing AQX-1125 as treatment in bladder pain syndrome/interstitial cystitis (BPS/IC)

    Potential market for BPS/IC is estimated to affect between 5 and 12 million people in the United States per year. Most BPS/IC patients continue to suffer this debilitating condition, despite treatment with existing therapies. Most current therapies and those in development are focused solely on symptomatic relief of BPS/IC.

    AQX-1125 could reach in U.S. alone peak revenue of $1.5-billion

    Pfizer and Johnson & Johnson own a significant amount in the company's shares.

    About AQX-1125

    All the clinical development utilize AQX-1125 tablets in an once-a-day dosing and has low plasma protein binding,being not metabolized and easily excreted unmetabolized in both urine and feces as per the first 7 clinical trials.

    -AQX-1125, Aquinox's lead drug candidate, is a small molecule activator of SHIP1, which is a regulating component of the PI3K cellular signaling pathway. By increasing SHIP1 activity

    -AQX-1125 accelerates a natural mechanism that has evolved to maintain homeostasis of the immune system and reduce immune cell activation and migration to sites of inflammation

    -AQX-1125 has demonstrated preliminary safety and favorable drug properties for once daily oral administration in multiple preclinical studies and seven completed clinical trials.

    Sentiment: Strong Buy

10.45-0.38(-3.51%)Apr 29 4:00 PMEDT